Condition Guide
Peptides for HIV-Associated Lipodystrophy
Tesamorelin (brand name Egrifta) is FDA approved for HIV-associated abdominal lipodystrophy. It is the only FDA-approved peptide specifically for this condition.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
How peptides help
Tesamorelin is a stabilized GHRH analog that increases endogenous GH pulses, reducing visceral adipose tissue by 15-18% in Phase III trials. Response is sustained as long as therapy continues.
Peptides researched for hiv-associated lipodystrophy
State of the evidence
FDA approved based on two Phase III trials. Real-world effectiveness aligns with trial data.
Frequently asked
Is tesamorelin only for HIV patients?
Its FDA approval is specific to HIV-associated lipodystrophy. Off-label use in visceral obesity and metabolic disease is common but not FDA-endorsed.
Related articles & guides
Growth Hormone Secretagogues Explained
Guide · 15 min
Peptides for Muscle Growth: What the Research Actually Shows
Guide · 12 min
Tesamorelin vs Sermorelin: GHRH Analogs Compared
Comparison · 8 min
Best Peptides for Muscle Growth & Recovery: What the Research Shows
Deep Dive · 13 min
Peptide Therapy Cost Breakdown 2026: What You Will Actually Pay
Analysis · 9 min